TR-002 for advanced solid tumors and pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced cancer that has spread, cannot be removed with surgery, and standard treatments no longer work or cause too many side effects.
- For the part of the study focusing on pancreatic cancer, you must have pancreatic cancer that has not responded to common chemotherapy drugs.
- You have adequate heart function shown by a recent heart test (ejection fraction over 50%).
- You are feeling well enough to be up and about (ECOG score 0–2).
- You agree to use effective birth control if you could become pregnant or get someone pregnant, from 1 month before until 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.